Demographic and clinical disease activity characteristics in patients treated with bDMARD and csDMARD. Values are median (interquartile range) unless otherwise specified.
| Characteristics | bDMARD, n = 79 | csDMARD, n = 30 | p |
|---|---|---|---|
| Female/male, n | 38/41 | 16/14 | NS |
| Age, yrs, mean (SD) | 52.7 (12.4) | 51.6 (12.3) | NS |
| Disease duration, yrs, mean (SD) | 7.8 (9.3) | 6.6 (8.2) | NS |
| TJC | 1 (0–2) | 5 (2–10.2) | 0.0001 |
| SJC | 0 (0–1) | 1 (0–3.2) | 0.0001 |
| PASI | 0.3 (0–0.6) | 1.5 (0–3.2) | 0.02 |
| Patients with axial involvement, n (%) | 30 (37.9) | 5 (16.6) | 0.03 |
| Patients with active enthesitis, n (%) | 18 (22.7) | 16 (53.3) | 0.004 |
| Patients with active dactylitis, n (%) | 4 (5) | 6 (20) | 0.02 |
| CRP, mg/dl | 0.3 (0.16–0.49) | 0.3 (0.2–0.76) | NS |
| PASDAS | 3.28 (2.69–3.72) | 4.43 (3.73–4.76) | < 0.01 |
| MDA 5/7, n (%) | 49 (62) | 5 (16.6) | < 0.01 |
| MDA 7/7, n (%) | 16 (20.2) | 3 (10) | NS |
| DAPSA | 6.8 (3.7–9.57) | 18.1 (16.5–31.5) | < 0.01 |
| cDAPSA | 6.5 (3.5–9.5) | 17.5 (11.2–26.9) | < 0.01 |
DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD; csDMARD: conventional synthetic DMARD; TJC: tender joint count; SJC: swollen joint count; PASI: Psoriasis Area Severity Index; CRP: C-reactive protein; PASDAS: Psoriatic Arthritis Disease Activity Score; MDA: minimal disease activity; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; NS: not significant.